Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. N. Azim has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extracellular vesicle-integrated brain organoid-on-a-chip systems for neuroimmune communication and precision therapy in viral encephalitis

    by Md. M. N. Azim

    Viral encephalitis causes substantial neurological morbidity and mortality through the combined effects of direct viral injury, blood–brain barrier (BBB) dysfunction, and dysregulated communication among neural, vascular, and immune cells. Extracellular vesicles (EVs) are increasingly recognized as mediators of this communication because they transfer proteins, lipids, viral constituents, cytokine-related signals, and regulatory RNAs between neurons, astrocytes, microglia, endothelial cells, and peripheral immune cells. Depending on their cellular origin and cargo, EVs may support antiviral defense or propagate viral dissemination, neuroinflammation, barrier injury, and persistent neurological sequelae. This narrative review synthesizes evidence for an EV–neuroimmune axis in viral encephalitis and evaluates how that evidence could inform the design of brain organoid-on-a-chip (BOoC) models. The review distinguishes established findings from a proposed integrated platform that would combine patient-derived brain organoids, a BBB-interposed vascular and immune compartment, real-time EV tracking, transendothelial electrical resistance and electrophysiological sensing, and multi-omics analysis. Existing studies support several individual components of this framework, but a fully integrated EV–BOoC system with closed-loop artificial intelligence (AI) control has not yet been demonstrated for viral encephalitis. Accordingly, digital twins, autonomous treatment optimization, and patient-specific clinical prediction are presented as future research directions rather than current capabilities. This calibrated framework identifies measurable design requirements, evidence gaps, and translational priorities for mechanistic studies, biomarker discovery, and precision therapeutic screening.

  • Open Access

    The “Dark Matter” of Tumors: Functional Roles of Non-Coding Neoantigens in Cancer Immunity

    by Sujay Kumar Bhajan, M. N. Azim, Atikur Rahman, Akhi Milon, Faizullah Al Numan, Rafsun Jany Rahat, Ataur Rahman, Maroua Jalouli, Jinwon Choi, Min Choi, et al.

    The non-coding regions (NCRs) of the genome, once called “dark matter” and considered useless, are now understood to be key to cancer immunity. While only 2% of the genome is protein-coding, some NCRs can produce small non-canonical peptides that originate from long non-coding RNAs (lncRNAs), untranslated regions, pseudogenes, transposable elements, or aberrant RNA transcripts. Recent advances in proteogenomics and immunopeptidomics have shown that these peptides can bind to major histocompatibility complex (MHC) molecules and be presented to the immune system, thereby constituting non-coding neoantigens (NCNAgs). Because they’re not typically found in healthy cells, the immune system can identify them as foreign. This helps CD8⁺ and CD4⁺ T cells recognize and destroy cancer cells. A similar mimicry at the viral level can activate the innate immune system via some of these signals. Compared with central immune tolerance observed for T antigens, NCNAgs show low expression in normal tissues and high antigenicity in tumors. Therefore, they are ideal candidates for cancer therapy. They could be used in personalized cancer vaccines, adoptive T-cell therapies, and as biomarkers that predict how well patients respond to immunotherapy. However, detecting these antigens is difficult, and limitations in current computational methods may lead to errors. Additionally, tumor heterogeneity, divergence in Human Leukocyte Antigen (HLA) types, and the risk of off-target effects complicate their use. Several emerging technologies, including AI-based prediction, ribosome profiling, and spatial multi-omics, are being applied to improve the accuracy of cancer inter-architecture mapping. In conclusion, targeting the non-coding genome may be a new approach in future cancer therapy.

  • Open Access

    Extracellular Vesicles from Senescent Stem Cells: A Converging Nexus Between Aging, Regeneration, and Cancer

    by M. N. Azim, Sujay Kumar Bhajan, Mithun Chandra Banik, Shihab Hussain, Sohel Rana, Sanjit Biswas, Tasnim Elin Islam, Sm Abu Sama Al Faruqee, Ataur Rahman, Maroua Jalouli, et al.

    Aging causes exhaustion of stem cells (SCs), loss of regenerative potential, and thereby makes them susceptible to age-related diseases (ARDs), known as cellular senescence. Senescent stem cells (SenSCs) secrete Senescence-Associated Secretory Phenotypes (SASPs) that synergistically exacerbate inflammation. Alongside this, they secrete Senescence-Derived extracellular vesicles (SenEVs) that carry a diverse array of molecules that transmit senescence-inducing signals to distant cells and tissues throughout the body, intensifying the detrimental effects of ageing and fostering a pro-tumorigenic microenvironment (PTME). In this review, we comprehensively assess these EVs, their distinct microRNA (miRNA) landscape, protein cargo, including extracellular matrix (ECM) remodeling enzymes and inflammatory cytokines, lipid profiles, and metabolomic signatures. Critically, we elucidate how SenEVs drive systemic ageing through paracrine transmission of senescence, impairing tissue regeneration by propagating oxidative stress, disrupting stem cell niches, and contributing to organ-specific ageing. Furthermore, we discussed their role as pro-cancer factors by remodeling the tumor microenvironment (TME), as they carry oncogenic miR-21 and miR-34a, which promote immune evasion and facilitate metastatic spread. Given their pervasive influence, SenEVs offer significant therapeutic opportunities, ranging from biomarkers of biological ageing to strategies to block harmful EVs and to engineer therapeutic EVs for targeted delivery. Future directions on SenEV research should focus on standardization, single-cell EV biology, organ-specific EV mapping, multi-omics integration, and AI-driven research. This integrated perspective underscores the profound clinical and global relevance of SenEVs as innovative targets for combating cancer and ARDs.

  • Open Access

    Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection

    by M. N. Azim, Sujay Kumar Bhajan, Jun Hong Park, Kasim Sakran Abass, Atikur Rahman, Min Choi, Jinwon Choi, Sohyun Park, Hyo Jeong Kim, Salima Akter, et al.

    Millions of new cancer cases and deaths worldwide annually demonstrate the pressing need for predictive preclinical models that go beyond standard two-dimensional (2D) cultures and animal systems. Recent developments in three-dimensional (3D) organoid technology have yielded a powerful platform for generating patient-specific mini-organ models that faithfully recapitulate primary tumors at the genetic, phenotypic, and architectural levels. Organoids retain functional fidelity by preserving key stem cell signaling pathways, including Wnt, Notch, and Hippo, making them robust platforms for disease modeling and high-throughput drug screening. This review describes representative organoid systems, ranging from patient-derived organoids (PDOs) to induced pluripotent stem cell (iPSC)-derived organoids, that serve as disease-specific “avatars” for personalized therapeutics. Predictive accuracy rates greater than 90% have been shown in clinical studies, providing evidence for the relevance of organoids in functional precision medicine. In addition to drug discovery, the extended use of organoids in regenerative oncology can provide a unique regulatory mechanism by selectively targeting CSCs and enhancing tissue repair after cytotoxic treatments. Recent advances in organoid-on-a-chip platforms, 3D bioprinting, and artificial intelligence (AI) address critical challenges involving vascularization, immune system integration, and scalability. With the advent of standardized, GMP-compliant platforms and recent regulatory initiatives, such as the FDA Modernization Act 2.0, organoids are well-positioned to support next-generation cancer research and therapy. This review aims to bridge the gap between stem cell-derived organoids (SCDOs), providing a fully humanized platform for preclinical cancer modeling and their clinical application, and to discuss their potential to advance ethically guided, personalized cancer therapeutics with improved predictive and translational power.


  • Open Access

    Therapeutic potential of ginseng and ginsenosides on muscle wasting disorders: Cachexia, sarcopenia, anorexia, and aging

    by Chang-Hwan Bae, Subramanian Muthamil, Ji Hyo Lyu, Jong Min Oh, Ung Cheol Shin, Maic Audo Eybi Mayer Sihombing, Thi Quynh Dan Nguyen, Seon-Wook Kim, Jong-Hoon Kim, Md M.N. Azim, et al.

  • Open Access

    Protective effects of Spirulina platensis on cadmium-induced hematobiochemical and histopathological alterations in broiler chickens

    by Iffat Kawsar, Iqramul Haque, M.N. Azim, Rahimul Islam Shuvo, Eftakhar Jahan Bhuiyan, Anandha Mozumder, M.A. Hashem, Kamrul Islam, Mohammad Musharraf Uddin Bhuiyan, Golzar Hossain, et al.